StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Other Oncology medicines by Quarter

Other Oncology medicines — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Other Oncology medicines: $27M in Q2 2026, down 10.0% from a year earlier.

Latest, Q2 2026
27
Period ended Jun 30, 2026
Change on a year earlier
-10.0%
30 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Other Oncology | 102 | | ( 4 ) | | ( 5 ) | | 2 | | 58 | | 69 | | ( 2 ) | | ( 5 ) | | 4 | | ( 15 ) | | ( 28 ) | | 27 | | ( 11 ) | | ( 3 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Oncology medicines — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202627-10.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202623-11.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202531-3.1%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202530-9.1%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025300.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202526-13.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202432+220.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202433+230.0%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202430+100.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202430+130.8%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202310+233.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202310+400.0%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202315+400.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202313+333.3%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20223-40.0%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20222-50.0%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up other Oncology medicines

Cite this data

StockData. (2026). AstraZeneca Other Oncology medicines ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-oncology-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.